ElectroCore Gets Expanded Approval in Canada for Device to Treat Adolescent Migraine

ElectroCore has received an amended medical device license from Health Canada, allowing it to expand the label of its gammaCore nVNS to include the acute and preventive treatment of migraine in adolescents age 12 to 17.

The label expansion was supported by results from a study of nine adolescents in whom 46.8 percent of all treated attacks were successfully resolved without the use of acute rescue medication.

The noninvasive, handheld device is applied at the neck to deliver an adjunctive therapy to treat migraine and cluster headache through mild electrical stimulation of the vagus nerve.

The device is now cleared for most forms of primary headache, including the acute and preventive treatment of migraine in adolescents and adults, as well as the acute and preventive treatment of cluster headache in adults, according to the Rockaway, N.J.-based company.